SMARCB1/INI-1-Deficient sinonasal carcinoma demonstrates a poor prognosis but favorable clinical outcomes after PD-1/PD-L1 inhibitor therapy: A case series
Open Access
- 31 January 2025
- journal article
- research article
- Published by SAGE Publications in Science Progress
- Vol. 108 (1)
Abstract
Despite advances in multimodal cancer therapy, such as combining radical surgery with high-intensity chemoradiotherapy, for SMARCB1/INI-1-deficient sinonasal carcinoma (SDSC), the prognosis of patients remains poor. Immunotherapy is gaining increasing popularity as a novel treatment strategy for patients with SMARCB1/INI-1-deficient tumors. Herein, we report on the management of three patients with SDSC who received PD-1/PD-L1 inhibitor therapy as a part of multimodal therapy based on surgery and chemoradiotherapy. All three patients survived and demonstrated good clinical remission and disease control. To our knowledge, this is the first case series reporting the use of immunotherapy to improve clinical outcomes in neoadjuvant, adjuvant, and late first-line stages of treatment in patients with SDSC. Furthermore, we reviewed the relevant literature and further explored the correlation between SMARCB1/INI-1 deletion and immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82272901)
This publication has 64 references indexed in Scilit:
- Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell linesBMC Cancer, 2016
- The Expanding Family of SMARCB1(INI1)-deficient NeoplasiaAdvances in Anatomic Pathology, 2014
- SMARCB1 (INI-1)-deficient Carcinomas of the Sinonasal TractAmerican Journal of Surgical Pathology, 2014
- SMARCB1(INI1)-deficient Sinonasal Basaloid CarcinomaAmerican Journal of Surgical Pathology, 2014
- The CARE Guidelines: Consensus‐Based Clinical Case Reporting Guideline DevelopmentHeadache: The Journal of Head and Face Pain, 2013
- Among Sinonasal Tumors, CDX-2 Immunoexpression is not Restricted to Intestinal-Type AdenocarcinomasHead and Neck Pathology, 2013
- NKX2-1/TTF-1: An Enigmatic Oncogene that Functions as a Double-Edged Sword for Cancer Cell Survival and ProgressionCancer Cell, 2013
- Sinonasal Undifferentiated Carcinoma (SNUC): The Alberta experience and literature reviewJournal of Otolaryngology - Head & Neck Surgery, 2013
- Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literatureEuropean Archives of Oto-Rhino-Laryngology, 2012
- Expression pattern of CK7, CK20, CDX-2, and villin in intestinal-type sinonasal adenocarcinomaJournal of Clinical Pathology, 2004